New imaging probe could spot hidden cancers earlier

NCT ID NCT06977945

Recruiting now Diagnosis Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Source: ClinicalTrials.gov ↗

First seen Jan 16, 2026 · Last updated Apr 25, 2026 · Updated 12 times

Summary

This study tests a new radioactive imaging agent called FL-091 to see how well it can find and stage certain cancers, including head and neck, colorectal, and pancreatic tumors. The agent targets a protein (NTSR1) that is common on these cancer cells but rare on healthy tissue. About 100 adults with suspected or confirmed NTSR1-positive tumors will receive FL-091 and undergo PET or SPECT scans. The goal is to improve early diagnosis and staging, which could guide better treatment decisions.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MALIGNANT TUMORS WITH POSITIVE NTSR1 EXPRESSION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Wuhan Union Hospital,China
RECRUITING

Wuhan, Hubei, 430030, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact

Conditions

Explore the condition pages connected to this study.

MALIGNANT TUMORS WITH POSITIVE NTSR1 EXPRESSION